ALK and non-small cell lung carcinoma: Crizotinib, an anaplastic lymphoma kinase (ALK)/ROS1/MET proto‐oncogene, receptor tyrosine kinase (MET) inhibitor, was the first targeted agent approved by the US Food and Drug Administration for the treatment of advanced ROS1‐rearanged NSCLC.